Our results that ATRA reduces TF mRNA and activity in NB4 cells are in agreement with previous results using this cell line [18, 20–22] and with results obtained with bone marrow cells from APL patients at different times after initiation of ATRA treatment [7, 19, 27]. The gene discussed is TF; the disease is acute promyelocytic leukemia.